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Abstract
 .Three missense mutations identified in the IDS gene of our Hunter’s disease patients P86L, P480L and P480Q and the
previously described P86R mutation were expressed in COS cells to evaluate their functional consequence on iduronate-2-
 .sulfatase IDS activity and processing. The 86-proline residue belongs to the highly conserved pentapeptide C-X-P-S-R in
which cysteine modification to a formylglycine is required for sulfatase activity. The substitution of the 86-proline residue
led to a severe mutation as no mature form was targeted to the lysosome in agreement with the severe phenotype observed
in patients carrying P86L and P86R mutations. Expression studies with P480L and P480Q mutant cDNAs showed the
presence of a small amount of 55 kDa mature form in the lysosomes of transfected COS cells. IDS activity of the P480L
and P480Q mutants in cell extracts represents 16.6% and 5.4% of the wild-type, respectively. q 1998 Elsevier Science B.V.
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1. Introduction
Iduronate-2-sulfatase or IDS EC 3.1.6.13; L-
.iduronate-2-sulfate 2-sulfohydrolase is one of the
lysosomal enzymes involved in the degradation of
heparan sulfate and dermatan sulfate. IDS deficiency
is responsible for mucopolysaccharidosis type II MPS
. w xII , a rare X-linked lysosomal storage disease 1 . A
broad spectrum of clinical phenotypes can be ob-
served, ranging from the mild form with late onset
and fairly normal intelligence to the severe form with
mental retardation and early death.
w xHuman IDS has been purified 2 and a 2.3-kb
cDNA clone containing the complete coding region
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was isolated and the reading frame contains 550
w xamino acids 3 . The gene spans approximately 24 kb
w xand contains 9 exons 4,5 . IDS processing steps have
been described in different cell lines: the 76-kDa
precursor is processed through various intermediates
w xforms to the 55-kDa and 45-kDa mature forms 6,7 .
Three missense mutations were identified in the
IDS gene of our patients: one previously described
 . w x  .P86L 8 and two unreported P480L and P480Q .
These three mutations and the previously described
w xP86R mutation 9,10 were expressed as the substitu-
tions of these two different prolines led to different
clinical phenotypes: a severe phenotype for the pro-
line 86, and a mild phenotype for the proline 480.
These four mutations were expressed in COS cells to
evaluate their functional consequence on IDS activity
and processing.
0925-4439r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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2. Materials and methods
2.1. Materials
Tritiated disaccharide substrate 0- a-L-
.  .idopyranosyluronic acid 2-sulfate - 1 “ 4 -2,5-
anhydro-D- 3H-mannitol-6-sulfate was purchased from
Prof. Krasnopolskaya University of Moscow, Rus-
.  .sia . The full-length IDS cDNA clone pB2Sc17 was
kindly provided by Prof. J.J. Hopwood Adelaide
Children’s Hospital, North Adelaide, 5006 South
.Australia, Australia . U.S.E mutagenesis kit and Pro-
tein A-Sepharose CL-4B were from Pharmacia. pTK
vector was from Clontech. Dulbecco’s modified Ea-
 .gle’s medium DMEM –25 mM HEPES was from
 .Gibco. Phenylmethyl-sulfonyl fluoride PMSF and
tunicamycin were from Sigma. Reagents for SDS-
PAGE and the Gene Pulser electroporation unit were
from Bio-Rad. Sequenase Quick-Denature Plasmid
Sequencing Kit, Thermosequenase cycle sequencing
kit, Amplify, and Rainbow 14C methylated protein
molecular-mass markers were from Amersham. Tran
35S-label and DMEM deficient in methionine and
cysteine were from ICN.
2.2. Patients: clinical data and identification of
mutations
2.2.1. Clinical data
Patients’ clinical data are presented in Table 1.
MPS II diagnosis was assessed by demonstrating a
high excretion of heparan sulfate and dermatan sul-
fate in urine and an undetectable IDS activity in
leukocytes and fibroblasts.
2.2.2. Identification of the mutations
Total RNA was extracted from fibroblasts by
guanidium isothiocyanatercesium chloride gradient
w xprocedure 11 and converted to cDNA using the
 .first-strand cDNA synthesis kit Pharmacia . IDS cD-
NAs were PCR-amplified in two fragments A and
. w xB using specific oligonucleotide primers 3 :
 .  X 32A 692 bp : primer 1 5 ACGAGGAGG-
51. X  X 580TCTCTGTGGCT rprimer 1 3 CGTGGA-
600 X .  .ACGGACTGTTTGTCT 5 B 123o bp :primer
 X 624 644 X .2 5 CACTAAGACATGTCGAGGGC 3
 X 1833rprimer 2 3 CCTCAATCTCGACCAG-
1854 X .CAAAAC 5
After amplification, PCR products were purified
on a 8% or 5% acrylamide gel and directly sequenced
with the Thermosequenase cycle sequencing kit using
w 33 xg P -ATP.
Genomic DNA was extracted from fibroblasts or
peripheral blood leucocytes to verify the presence of
w xthe mutation 12 .
2.3. Expression studies
2.3.1. Constructs
IDS cDNA mutants were generated by site-di-
rected mutagenesis using the U.S.E. mutagenesis kit.
Each mutant was constructed using one single-
stranded vector pTK–IDS containing the normal
.IDS cDNA and two oligonucleotides: one mutagenic
oligonucleotide containing the desired mutation and
the Mut-XhoI oligonucleotide to abolish the unique
XhoI restriction site in the vector for selection of
mutated plasmids. The sequences of these oligo-
Table 1
Patient’s data
Case Patient 1 Patient 2 Patient 3
Phenotype Severe Mild Mild
 .Age at last examination 13 yrs 18 yrs 45 yrs
Mental retardation qqq y y
Coarse facies qqq yrq yrq
Joint stiffness qq yrq q
Dysostosis qq y qq
Genotype
 .  .  .Mutation P86L 381 C“T P480L 1563 C“T P480Q 1563 C“A
Exon III IX IX
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Table 2
Oligonucleotides used for mutagenesis
Oligonucleotides Sequences
X XP86L 5 GCAGTGTGCGCCCTGAGCCGCGTTTC 3
X XP86R 5 GCAGTGTGCGCCCGGAGCCGCGTTTC 3
X XP480L 5 GGAATTCTGACAAGCTGAGTTTAAAAGA 3
X XP480Q 5 GGAATTCTGACAAGCAGAGTTTAAAAGA 3
X XMut-XhoI 5 GCTCGACGGTACTCGCGGAACTGAAAAACC 3
nucleotides are indicated in Table 2. The sequence of
mutated plasmids was verified by using the kit.
2.3.2. Transfection procedure
COS cells were cultivated in DMEM–25 mM
HEPES, supplemented with 1 mM pyruvate sodium,
 .12% vrv fetal calf serum and antibiotics. COS cells
were electroporated with an eukaryotic vector con-
 .taining the normal pTK–IDS or mutated IDS cDNA
under the control of the Thymidine Kinase promoter.
The experimental conditions were: 20.106 cells in
500 ml of DMEM–25 mM HEPES, 100 mg of
plasmid DNA and a voltage pulse of 220 V, 960 mF.
2.4. Pulse-chase labelling, immunoprecipitation and
IDS acti˝ity measurement
Experimental conditions have been previously de-
w xscribed 6 .
3. Results
3.1. Identification of the mutations
The severely affected patient 1 has a C“T transi-
tion at nucleotide 381 of the cDNA that produces
Pro“Leu substitution in codon 86. This mutation
partially activates a cryptic splice acceptor site 28 bp
.downstream the mutation leading to two different
transcripts: one transcript containing the P86L muta-
tion, and another with a deletion of 44 bp starting at
 .nucleotide 365 of the cDNA data not shown . This
deletion changes two amino acids and creates a stop
codon in codon 83. This truncated polypeptide is
unable to give any mature form as reported for other
w xnonsense mutations in the IDS gene 6,13 . The
mildly affected patients 2 and 3 have a C“T transi-
tion and a C“A transversion at nucleotide 1563 of
the cDNA leading to Pro“Leu and Pro“Gln sub-
stitutions in codon 480, respectively. These mutations
identified both by sequencing of the cDNA and the
genomic DNA were also confirmed by allele-specific
oligonucleotide hybridization.
3.2. Expression of IDS mutant cDNAS
P86L, P86R, P480L and P480Q mutants were
transiently expressed in COS cells. 35S-labeled wild-
type and mutant IDS polypeptides were immunopre-
cipitated from cell homogenates after a 3-h pulse
period or after a subsequent 24-h chase, and analysed
 .by SDS-PAGE Fig. 1 . After a 3-h pulse, COS cells
Fig. 1. 35S Pulse-chase labeling of COS cells transiently transfected with wild-type and IDS mutant cDNAs. Exposure time was 4 days
 .except for P480Q cell extracts after a 24-h chase 20 days .
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Table 3
IDS activity in COS cells transfected with wild-type and mutant
cDNAs







IDS activity values are the average of four different transfections
transfected with either the P86L or the P86R mutant
cDNA produced the 76-kDa precursor rapidly con-
 .verted to a 62-kDa form Fig. 1 . No 90-kDa precur-
sor could be visualized. After a 24-h chase, no 55-kDa
mature form was produced while the 76- and 62-kDa
polypeptides were degraded. No increase of IDS
activity in these transfected cells was observed Table
.3 .
The 76- and 90-kDa precursor forms were visual-
ized after a 3-h labeling period in COS cells trans-
fected with either the P480L or the P480Q mutant
 .cDNA Fig. 1 . A small amount was processed to the
55-kDa mature form after a 24-h chase. More 55-kDa
mature form was produced by P480L than by P480Q
mutant. In these transfected cells, IDS activity pro-
duced by the P480L and P480Q mutants represents
16.6% and 5.4% of the wild-type, respectively Table
.3 .
4. Discussion
The functional importance of the prolines at posi-
tion 86 and 480 was investigated as the substitutions
affecting these prolines led to a severe and a mild
phenotype, respectively.
In cells transfected with the P86L and P86R IDS
mutant cDNAs, no lysosomal mature forms and no
increase of IDS activity could be detected. These
results are in agreement with the severe phenotype
observed in patient 1 and others with the P86L or
w xP86R mutations 8–10 . The P86L and P86R muta-
tions affect the proline residue of the C-X-P-S-R
w xsequence highly conserved in all sulfatases 14 . In
this pentapeptide, the early conversion in the endo-
plasmic reticulum of the cysteine to a formylglycine
is required for sulfatase activity and its deficiency
 . w xcauses multiple sulfatase deficiency MSD 15,16 .
Expression studies performed on MSD cells showed
that the absence of the modification does not prevent
maturation of arylsulfatase A and IDS precursor forms
w x17,18 . Similar results were obtained when this con-
served cysteine was mutated either to a serine residue
w xin N-acetylgalactosamine 4-sulfatase 19 or to a
w xthreonine residue in IDS 18 . In contrast to this
cysteine residue, the conserved proline residue, close
or even part of the IDS active site appears as essen-
tial for the proper folding and processing of IDS.
The 480 proline residue is localized in a poorly
conserved region of the IDS gene. Expression studies
showed that the P480L and P480Q precursor forms
were very poorly processed to the lysosomal 55-kDa
mature form compared to COS cells transfected with
the wild-type IDS cDNA. IDS activity of the P480L
and P480Q mutants represents 16.6% and 5.4% of
the wild-type respectively, when measured in cell
extracts. As IDS precursors are catalytically active in
w xvitro 7 , subcellular fractionation was performed to
evaluate the percentage of IDS activity in the lyso-
somes of transfected COS cells. No significant in-
crease of IDS activity could be measured in the
lysosomal fraction of these transfected cells when
compared to the basal activity of COS cells lyso-
somes because of the small amount of mature forms
produced by these mutants. IDS activity measurement
in patient cells cannot discriminate between a com-
plete deficiency and a very low residual IDS activity,
but a low enzyme activity is enough to allow a
w xnormal phenotype in most lysosomal diseases 20 .
The small amount of the 55-kDa lysosomal mature
form observed in Fig. 1 probably retains enough
activity to confer a mild phenotype to patients 2 and
3.
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